EPIGRAL vs INDOAMIN: Stock Comparison

EPIGRAL vs INDOAMINUpdated 11 Sept 26, 4:08 PM ISTNSE & company filings

EPIGRAL is the larger company by market capitalisation. EPIGRAL shows a higher dividend yield, faster revenue growth and lower leverage, while INDOAMIN shows a lower P/E, a higher ROE and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

EPIGRAL leads 8; INDOAMIN leads 5 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

EPIGRALINDOAMIN

Valuation lens

What price are you paying?

Market CapContext only
₹4,888 Cr
₹928 Cr
P/E RatioINDOAMIN has the lower reading
18.03x
11.47x
P/B RatioEPIGRAL has the lower reading
2.2x
2.37x
EPSEPIGRAL has the higher reading
₹22.99
₹4.22
Book ValueContext only
₹514.92
₹54.25
Dividend YieldEPIGRAL has the higher reading
0.44%
0.39%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
EPIGRAL is the larger company
₹4,888 Cr vs ₹928 Cr
P/E Ratio
INDOAMIN has a lower P/E
11.47x vs 18.03x
P/B Ratio
EPIGRAL has a lower P/B
2.2x vs 2.37x
EPS
EPIGRAL has higher earnings per share
₹22.99 vs ₹4.22
Dividend Yield
EPIGRAL has a higher dividend yield
0.44% vs 0.39%
Revenue Growth (TTM YoY)
EPIGRAL has faster revenue growth
17.3% vs 11.3%
EPS Growth (TTM YoY)
INDOAMIN has faster EPS growth
76% vs -6.8%
Qtr Sales Growth
EPIGRAL has stronger quarterly sales growth
0% vs -1.96%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricEPIGRALINDOAMIN
SectorChemicalsChemicals
IndustrySpecialty ChemicalsSpecialty Chemicals

Price

MetricEPIGRALINDOAMIN
Live Price₹1,131.1₹137.95
Day Change-1.63%-1.75%
Volume22,4251.39 L
52-Week High₹1,808.8₹149
52-Week Low₹807₹81.9
Distance from 52W High-37.47%-7.42%

Valuation

MetricEPIGRALINDOAMIN
Market Cap₹4,888 Cr₹928 Cr
P/E Ratio18.03x11.47x
P/B Ratio2.2x2.37x
EPS₹22.99₹4.22
Book Value₹514.92₹54.25
Dividend Yield0.44%0.39%

Growth

MetricEPIGRALINDOAMIN
Revenue Growth (TTM YoY)17.3%11.3%
EPS Growth (TTM YoY)-6.8%76%
Qtr Sales Growth0%-1.96%
Qtr Profit Growth-0.56%-0.48%

Profitability & Leverage

MetricEPIGRALINDOAMIN
ROE14.94%20.14%
ROCE11.04%13.9%
Net Margin13.14%6.84%
Operating Margin16.37%11.2%
Debt to Equity0.25x0.79x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricEPIGRALINDOAMIN
Promoter Holding68.83%58.42%
FII Holding1.03% 0.51 pp0.08% 0.06 pp
DII Holding5.56% 0.66 pp0%
Public Holding24.55% 0.15 pp41.5% 0.06 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: EPIGRAL and INDOAMIN.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.